MedPath

Hemodynamic Effects of BPA at Rest and During Exercise in CTEPH

Not Applicable
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Diagnostic Test: Invasive exercise testing
Registration Number
NCT04052243
Lead Sponsor
Aarhus University Hospital
Brief Summary

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by obstruction of the pulmonary vasculature by residual organized thrombi, leading to increased pulmonary vascular resistance (PVR), progressive pulmonary hypertension, and right heart failure.

Medical therapy and balloon angioplasty (BPA) are effective treatment alternatives in lowering pulmonary pressures and increasing pulmonary flow.

The aim of this study is to assess the hemodynamic effects of BPA or medical therapy on the pressure-flow relationship in the pulmonary vasculature and the pulmonary vascular compliance.

Detailed Description

Chronic thromboembolic pulmonary hypertension \[CTEPH\] is a rare condition with a significant risk of morbidity and mortality. The primary cause of CTEPH is thrombotic lesions, which did not resolve after acute pulmonary embolism. This causes increased pulmonary vascular resistance \[PVR\], leading to secondary remodeling of pulmonary arteries causing pulmonary hypertension and ultimately progressive right heart failure. The treatment of choice is surgical pulmonary endarterectomy \[PEA\], however up to 40% cases are not treated surgically, due to operability, anatomic location of the lesions, patient choice and comorbidities significantly increasing procedural risk. A new alternative procedure, balloon pulmonary angioplasty \[BPA\] has been proposed for patients with inoperable CTEPH or persistent pulmonary hypertension after pulmonary endarterectomy (PEA) and is currently characterized with good outcome in functional capacity, hemodynamic parameters, biomarkers, and health-related quality of life.

Exercise stress tests of the pulmonary circulation are used in workup and diagnosis of pulmonary hypertension as a hemodynamic abnormality. The approach has allowed identification of patients with normal or marginally increased mPAP at rest but with symptomatic increases in mPAP at exercise, related to either increased resistance or increased left atrial pressure. Although this differential diagnosis is of obvious therapeutic relevance, guidelines about exercise stress studies of the pulmonary circulation have not been developed until now for lack of robust evidence allowing for a consensus on clearly defined cutoff values.

Neither the pathophysiology of the exercise limitation nor the underlying mechanisms of the BPA - induced improvement were studied before. Therefore the aim of this study is to assess the hemodynamic effects of BPA treatment on the pressure-flow relationship in the pulmonary vasculature and the pulmonary vascular compliance. Furthermore, the investigators will explore possible differences in treatment effect across centers. Especially explore the timing of medical therapy vs balloon angioplasty.

.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria

-Patients with CTEPH or CTED eligible for balloon pulmonary angioplasty.

Exclusion Criteria

-Patients unable to perform ergometer exercise

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
All patientsInvasive exercise testingExercise is added to resting right heart catheterization
Primary Outcome Measures
NameTimeMethod
Slope of mPA/CO after BPA6 months after last BPA session

Change from Baseline in Slope of mean pulmonary artery pressure/cardiac output after BPA at 6 months

Secondary Outcome Measures
NameTimeMethod
Change in resting PVR after BPA6 months after last BPA session

Change from Baseline in pulmonary vascular resistance (PVR) after BPA at 6 months

Change in 6 MWT after BPA6 months after last BPA session

Change from Baseline in 6 minute walk test (MWT) after BPA at 6 months

Change in NT-proBNP after BPA6 months after last BPA session

Change from Baseline in NT-proBNP after BPA at 6 months

Trial Locations

Locations (3)

Department of cardiology, Aarhus University Hospital

🇩🇰

Aarhus, Denmark

European Health Center

🇵🇱

Otwock, Poland

Nagoya University Hospital

🇯🇵

Nagoya, Japan

© Copyright 2025. All Rights Reserved by MedPath